Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Invested Capital (2018 - 2025)

Historic Invested Capital for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $6.8 million.

  • BioNexus Gene Lab's Invested Capital fell 2739.52% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 2739.52%. This contributed to the annual value of $8.3 million for FY2024, which is 1382.34% down from last year.
  • As of Q3 2025, BioNexus Gene Lab's Invested Capital stood at $6.8 million, which was down 2739.52% from $7.5 million recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's Invested Capital peaked at $9.7 million during Q3 2023, and registered a low of $6.0 million during Q2 2023.
  • Its 5-year average for Invested Capital is $7.6 million, with a median of $7.2 million in 2022.
  • As far as peak fluctuations go, BioNexus Gene Lab's Invested Capital surged by 6006.25% in 2024, and later plummeted by 2739.52% in 2025.
  • BioNexus Gene Lab's Invested Capital (Quarter) stood at $7.2 million in 2021, then decreased by 7.61% to $6.7 million in 2022, then skyrocketed by 44.9% to $9.7 million in 2023, then fell by 13.82% to $8.3 million in 2024, then dropped by 18.1% to $6.8 million in 2025.
  • Its Invested Capital was $6.8 million in Q3 2025, compared to $7.5 million in Q2 2025 and $7.8 million in Q1 2025.